Latest for IgA Vasculitis with Nephritis
See all trialsThe week in rare diseaseEach date is the day a change was posted. Open an item to see where things stand now.
More about IgA Vasculitis with Nephritis
IgA-dominant glomerulonephritis develops in approximately 40-50% of patients with systemic disease; when kidney biopsy performed in all patients, IgA deposition found in ~100%. The glomerulonephritis ranges from microscopic hematuria and mild proteinuria to rapidly progressive glomerulonephritis with crescents requiring urgent intervention.
Keep reading about IgA Vasculitis with Nephritis
About 1-5% of children progress to end-stage renal disease requiring dialysis or transplantation, while progression rates are significantly higher in adults (5-10% at 5 years). GI manifestations range from mild abdominal pain to life-threatening gastrointestinal bleeding requiring transfusion and endoscopic intervention.
Secondary complications including HUS (hemolytic uremic syndrome) and pulmonary hemorrhage occur occasionally. Elevated serum IgA level is characteristic but not diagnostic, as elevated IgA occurs in other conditions. Most children achieve complete remission of systemic disease, though renal involvement duration and severity predict persistent or progressive renal disease.
What are the symptoms of IgA Vasculitis with Nephritis?
These are common symptoms of IgA Vasculitis with Nephritis, and how strong they are varies from person to person.
- Palpable purpura on lower extremities and buttocks
- Arthritis and arthralgias
- Glomerulonephritis with hematuria and proteinuria
- Abdominal pain and GI bleeding
- Renal dysfunction and hypertension
- Elevated serum IgA levels
Who gets IgA Vasculitis with Nephritis?
Most common in children ages 3-10 years with peak incidence 4-6 years, though can occur at any age from infancy to elderly. Slight male predominance at approximately 1.5:1 to 2:1 male-to-female ratio. Significantly higher prevalence in East Asian populations (particularly Japan, Korea, China) and Mediterranean populations compared to Northern European and African populations.
Estimated prevalence varies 5-10 fold between populations. Seasonal variation with increased incidence in autumn and winter correlating with upper respiratory infections. Often preceded by upper respiratory infection or other infectious trigger 1-2 weeks prior to symptom onset. Recurrent or persistent hematuria occurs in approximately 40% of patients even after systemic disease resolution.
Next steps: find trials you might fitsee what is being testedget help payingget alerts
Side effects people have reported to the FDA
Side effects people have reported to the FDA
Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.
Loading side effect data...
Diagnosis and genetic testing
Genetic testing for IgA Vasculitis with Nephritis
Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.
Finding labs...
Trusted IgA Vasculitis with Nephritis resources
Reputable organizations and medical references for learning more about IgA Vasculitis with Nephritis, including disease registries, foundation resources, and clinical guidelines.